Dan Samorodnitsky - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Dan Samorodnitsky's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Dan Samorodnitsky
Verified
Freelance Writer and Journalist, Freelance
Minneapolis
Beats
Science Biology Climate Change Genetic Engineering
Insurance
Content
By Dan Samorodnitsky Verified| BioSpace Verified Verve Therapeutics’ in vivo base editing therapy, VERVE-102, lowered bad cholesterol in Phase Ib, the company announced Monday morning, leaving the company’s partner, Eli Lilly, with a decision to make. Analysts from both William Blair and BMO Capital Markets pointed to the asset’s “clean” safety profile in notes to investors Monday morning. Safety was the trial’s primary outcome.
By Dan Samorodnitsky Verified| BioSpace Verified Tuesday was a good day for Bristol Myers Squibb, with the pharma notching two key cancer wins—one with the FDA and another in the courtroom. The regulator cleared the combination of the PD-1 blocker Opdivo and the anti-CTLA4 antibody Yervoy as a first-line treatment for patients with unresectable or metastatic colorectal cancer (CRC). The FDA’s approval covers patients carrying the specific genetic profiles, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).
By Heather McKenzie Verified, Jef Akst Verified, Annalee Armstrong Verified, Dan Samorodnitsky Verified| BioSpace Verified > Listen on Spotify> Listen on Apple Products> Listen on Amazon Music> Listen on iHeartPushback against the Trump administration’s massive government cuts exploded this weekend across America—and biopharma is no exception. Taking a deep dive into the leadership cuts, we found that more than half of the senior FDA leaders from six months ago are no longer there, and that’s just the leadership.
Company Info
Freelance
Freelancer.com is the largest freelancing and crowdsourcing marketplace in the world, connecting over 81 million employers and freelancers across more than 247 countries. Founded in 2009 and based in Sydney, Australia, the platform allows employers to post jobs while freelancers can bid on these projects. It is publicly traded on the Australian Securities Exchange under the ticker ASX:FLN. The platform supports a variety of work categories, including software development, writing, design, and marketing. Freelancer.com also offers contests for creative work, where employers can award prize money to winning entries. Users can choose from different membership plans, including free and paid subscriptions, which provide various benefits. The mobile app enhances project management and communication for users on the go. With a diverse customer base that includes individuals, small businesses, and large enterprises, Freelancer.com plays a significant role in the global online economy.
De Pere, Wisconsin, United States